Veloxis Pharmaceuticals A/S
126 articles with Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the first three months of 2019.
The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67, hereby convenes the annual general meeting in the Company which will be held on
Veloxis Pharmaceuticals A/S (OMX: VELO) today releases its Annual Report for the financial year 2018.
Veloxis Pharmaceuticals A/S today announces the promotion of Mark Hensley to Chief Commercial Officer.
Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in de novo kidney transplant patients in combination with other immunosuppressants.
Veloxis Pharmaceuticals A/S today announces the promotion of Ira Duarte to Chief Financial Officer. Ms. Duarte has served as the vice-president of finance for Veloxis Pharmaceuticals, Inc. since February 2016 where she has been responsible for all finance and accounting related functions including financial reporting, treasury, budgeting and tax.
Veloxis Pharmaceuticals A/S announced today that CEO Craig Collard will present at the Jefferies 2018 London Healthcare Conference at 8:00 AM GMT on Thursday, November 15, 2018.
Veloxis upgrades 2018 Outlook based on strong performance.
Veloxis Partners with the American Society of Transplant Surgeons to Award First Annual ASTS-Veloxis Fellowship in Transplantation
Veloxis Pharmaceuticals A/S is pleased to announce an ongoing partnership with the American Society of Transplant Surgeons (ASTS) to support the fellowship training of a transplant surgeon with the ASTS-Veloxis Fellowship in Transplantation.
Product revenue for Q1 2018 was an increase of 142% compared to the same period last year.
Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company's supplemental New Drug Application (sNDA) which seeks a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants
Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten Marott is joining the company as its new Chief Financial Officer.
Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®
Veloxis Pharmaceuticals A/S is pleased to announce the publication of Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients in the March 2018 issue of the American Journal of Kidney Diseases.
Veloxis Pharmaceuticals A/S announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.
Veloxis today announced that it has obtained $60M of capital from funds managed by Athyrium.
Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2017
Here's a table that provides the total number of shares and voting rights in Veloxis as of 31 December 2017.
The purpose of the grant of warrants is to reflect the Company's objective to incentivize long-term shareholder value creation.
As a result of the employee’s investment in the Company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 520,164.
Veloxis reported a net loss of tUSD 8,421 for the first nine months of 2017 compared to a net loss of tUSD 23,961 for the same period in 2016.
Today, the Board of Directors of Veloxis The company has decided to issue and grant warrants to 43 employees of the Company under the existing Warrant Program.